Epithelial cell adhesion molecule (EpCAM) plays a critical role in tumorigenesis and is an ideal tumor target due to high expression on various solid tumors, including head and neck, colorectal, anaplastic thyroid cancer, lung, and esophageal cancers.
AM-928, a novel humanized anti-EpCAM antibody, exhibits remarkable inhibitory activity on EpCAM downstream signaling cascade, leading to decrease of cancer stemness and enhanced cancer cell apoptosis. In addition, AM-928 can induce antibody dependent cell mediated cytotoxicity via the high specificity and binding affinity. The in vitro studies showed that AM-928 is effective in targeting a broad range of EpCAM-expressing cancers. The in vivo studies have demonstrated AM-928’s ability to suppress tumor growth and metastasis. These results suggest that AM-928 could be an effective treatment for EpCAM-expressed solid tumors.
In early 2023, AM-928 IND was cleared by US FDA and Taiwan TFDA. Phase 1 clinical trial of AM-928 is ongoing in subjects with advanced solid tumors.
